Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

Researchers found that inhibiting GSK-3 led to less defects in the axonal transport process and less neuronal cell death, while inhibiting ERK1 led to more transport problems and more cell death.

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated huntingtin ...

University at Buffalo researchers shed some light on an enduring neuroscience mystery: How exactly does a mutated ...

Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B) ...

Actuate Therapeutics, Inc. announced that data on their investigational drug elraglusib, designed to treat advanced salivary gland carcinoma by inhibiting glycogen synthase kinase-3 beta (GSK-3β ...